KRAS and non-small cell lung carcinoma: The development of KRAS-G12C inhibitors (KRAS-G12Ci), such as sotorasib and adagrasib, have shown promising results in clinical trials, demonstrating moderate benefits for previously treated KRAS-G12C mutant NSCLC patients, although overall survival remains unimproved [7, 8].